neuraminidas
na
gene
influenza
viru
isol
infect
patient
analys
circul
oseltamivirresist
virus
brazil
report
previous
clinic
sampl
collect
state
rio
grand
sul
rs
two
na
inhibitorresist
mutant
identifi
one
studi
reveal
low
preval
resist
virus
spread
resist
mutant
throughout
rs
sinc
april
influenza
viru
refer
spread
worldwid
primari
treatment
infect
patient
antivir
drug
oseltamivir
neuraminidas
inhibitor
nai
hurt
et
al
oseltamivirresist
influenza
rare
nevertheless
case
report
around
world
august
common
mutat
associ
oseltamivir
resist
amino
acid
chang
neuraminidas
na
protein
sheu
et
al
kiso
et
al
renaud
et
al
howev
mutat
describ
season
influenza
virus
sheu
et
al
circul
oseltamivirresist
virus
brazil
report
previous
aim
studi
detect
resist
influenza
isol
state
rio
grand
sul
rs
assess
possibl
spread
resist
virus
patient
sever
acut
respiratori
syndrom
sar
characteris
fever
cough
dyspnoea
myalgia
arthralgia
gastrointestin
symptom
malais
ssr
report
brazil
rs
report
sar
case
report
brazilian
state
among
confirm
revers
transcriptionpolymeras
chain
reaction
rtpcr
viru
detect
reappear
confirm
case
winter
season
juneaugust
rs
gregianini
et
al
present
studi
analys
clinic
sampl
rs
collect
sampl
randomli
select
independ
clinic
sampl
sar
patient
collect
julynovemb
sampl
includ
clinic
sampl
nasopharyng
aspir
swab
obtain
central
laboratori
public
health
govern
laboratori
involv
pandem
diagnosi
rs
sampl
previous
confirm
posit
sar
realtim
rtpcr
detect
accord
procedur
recommend
center
diseas
control
prevent
atlanta
ga
usa
research
approv
ethic
committe
lutheran
univers
brazil
protocol
determin
whether
viru
isol
harbour
genet
marker
associ
resist
antivir
drug
sequenc
na
gene
determin
briefli
viral
rna
extract
use
either
qiaamp
viral
rna
mini
kit
qiagen
hilden
germani
newgen
preppreamp
kit
simbio
cachoeirinha
brazil
rtpcr
perform
reaction
volum
contain
mmlv
buffer
promega
dntp
ge
healthcar
u
rnaseout
promega
u
mmlv
rt
promega
u
taq
dna
polymeras
cenbiot
primer
idt
naf
nar
nest
amplif
perform
reaction
volum
contain
taq
buffer
mm
mgcl
dntp
ge
healthcar
u
taq
dna
polymeras
cenbiot
nest
primer
idt
naf
nar
amplif
programm
follow
rtpcr
cycl
min
min
cycl
sec
sec
min
final
cycl
min
ii
nest
pcr
min
cycl
sec
sec
min
final
cycl
min
amplicon
bp
analys
agaros
gel
electrophoresi
sequenc
reaction
perform
use
bigdy
termin
version
cyfinanci
support
faperg
cle
sequenc
kit
appli
biosystem
life
technolog
co
foster
citi
ca
usa
pmol
intern
primer
ng
dna
na
pcr
product
sequenc
use
abi
prism
xl
dna
analyz
appli
biosystem
foster
citi
ca
usa
consensu
sequenc
obtain
use
programm
seqman
lasergen
dnastar
madison
wi
nest
rtpcr
yield
na
amplicon
sampl
sequenc
analysi
show
mutat
na
absent
sampl
except
one
sampl
male
patient
collect
august
patient
year
old
live
citi
clinic
record
mention
immunosuppress
patient
fever
dyspnoea
hospitalis
ario
grand
genbank
access
na
amino
acid
chang
also
shown
associ
oseltamivir
resist
season
influenza
virus
sheu
et
al
deyd
et
al
hurt
et
al
analysi
na
mutat
brazilian
patient
reveal
mutat
present
one
isol
collect
clinic
record
associ
sampl
indic
patient
threemonthold
boy
citi
die
hospitalis
patient
syndrom
exhibit
fever
cough
dyspnoea
hospitalis
ario
grand
genbank
access
mutat
identifi
clinic
specimen
isol
season
influenza
virus
asiapacif
region
sheu
et
al
hurt
et
al
mutat
associ
reduc
nai
sensit
previous
describ
pandem
influenza
associ
mutat
mutat
result
extrem
high
level
oseltamivir
resist
sheu
et
al
boltz
et
al
hurt
et
al
zanamivir
anoth
nai
recommend
treatment
influenza
mutat
associ
zanamivir
resist
occur
predominantli
season
influenza
exampl
mutat
includ
gad
sheu
et
al
deyd
et
al
hurt
et
al
studi
zanamivir
resist
mutat
observ
sampl
na
inhibitor
zanamivir
oseltamivir
market
treatment
prophylaxi
influenza
stockpil
mani
countri
use
pandem
although
recent
surveil
identifi
strike
increas
frequenc
oseltamivirresist
season
influenza
virus
europ
usa
oceania
south
africa
report
signific
zanamivir
resist
among
virus
cluster
oseltamivirresist
infect
describ
hospitalis
immunocompromis
patient
among
immunocompet
patient
commun
demonstr
potenti
persontoperson
spread
resist
strain
clinic
impact
resist
influenza
appear
signific
immunocompet
patient
could
major
threat
immunocompromis
patient
renaud
et
al
resist
virus
readili
emerg
patient
virus
replic
higher
titr
longer
period
immunocompromis
host
immunocompet
host
ison
et
al
nai
introduc
oseltamivir
resist
rate
season
influenza
isol
low
influenza
season
follow
year
mani
countri
report
extrem
high
rate
oseltamivir
resist
season
isol
dharan
et
al
resist
caus
amino
acid
substitut
na
protein
virus
meijer
et
al
mutat
becam
common
despit
low
use
oseltamivir
spread
throughout
world
almost
replac
season
influenza
virus
subsequ
low
rate
oseltamivirresist
report
mani
countri
hurt
et
al
renaud
et
al
storm
et
al
howev
higher
frequenc
detect
studi
sever
countri
includ
spain
detect
patient
sever
influenza
ledesma
et
al
australia
singapor
overal
frequenc
oseltamivir
resist
asiapacif
region
hurt
et
al
studi
found
similar
rate
oseltamivir
resist
overal
preval
oseltamivirresist
virus
studi
indic
viru
mutat
spread
rs
studi
identifi
one
isol
mutat
one
mutat
na
protein
preval
mutant
low
rs
evid
oseltamivir
zanamivirresist
mutant
spread
throughout
rs
suggest
antivir
drug
appropri
treatment
